Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis ; volume:17 ; number:1 ; day:4 ; month:10 ; year:2019 ; pages:1-7 ; date:12.2019
Pediatric rheumatology ; 17, Heft 1 (4.10.2019), 1-7, 12.2019
- Creator
-
Renton, William D.
Leveret, Helen
Guly, Catherine
Smee, Heather
Leveret, Jamie
Ramanan, Athimalaipet V.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12969-019-0366-x
- URN
-
urn:nbn:de:101:1-2020020720102954985882
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Renton, William D.
- Leveret, Helen
- Guly, Catherine
- Smee, Heather
- Leveret, Jamie
- Ramanan, Athimalaipet V.
- SpringerLink (Online service)
Other Objects (12)
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab